Latham & Watkins Advises Genascence in Series A Financing

A California-based team advises the clinical-stage biotechnology company in the funding round.

May 12, 2022

Genascence Corporation (Genascence), a clinical-stage biotechnology company revolutionizing the treatment of prevalent musculoskeletal diseases with gene therapy, has announced it has completed the first closing in a Series A financing led by Pacira BioSciences, Inc., totaling US$10.5 million. Additional investors included Polymerase Capital, DeepWork Capital, and University of Florida Research Foundation.

Latham & Watkins Advises Genascence in the funding round with a deal team led by Bay Area partners Ben Potter and Judith Hasko, with Century City associate Simon Moshkovich.

Notice: We appreciate your interest in Latham & Watkins. If your inquiry relates to a legal matter and you are not already a current client of the firm, please do not transmit any confidential information to us. Before taking on a representation, we must determine whether we are in a position to assist you and agree on the terms and conditions of engagement with you. Until we have completed such steps, we will not be deemed to have a lawyer-client relationship with you, and will have no duty to keep confidential the information we receive from you. Thank you for your understanding.